Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Study Summary

The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.

Conditions

Metastatic NSCLC - Non-Small Cell Lung Cancer Locally Advanced NSCLC - Non-Small Cell Lung Cancer

Interventions / Drugs

inupadenant Placebo Carboplatin Pemetrexed

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment36 participants

Primary Completion—

Lead SponsoriTeos Therapeutics

Data Retrieved2026-04-11 04:18:14.528901+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.